Navigation Links
Pharmasset Presents Clevudine and Racivir Data at the International,HIV Drug Resistance Workshop

p>About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates: Clevudine for the treatment of chronic HBV infection, which is expected to enter US, European and South American Phase 3 registration clinical trials and is already approved for HBV in Korea and marketed by Bukwang Pharmaceuticals under the brand name Levovir; R7128, an oral treatment for HCV, in a Phase 1 clinical trial through a strategic collaboration with Hoffmann-LaRoche; and Racivir for the treatment of HIV in combination with other approved HIV drugs, which has completed a Phase 2 clinical trial.

    Contact

    Alan Roemer, Vice President

    Investor Relations & Corporate Communications

    

    Office: (609) 613-4125

alan.roemer@pharmasset.com

Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performances or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We describe in greater detail many of the risks that may impact management's expectations under the caption "Risk Factors" in the company's quarterly report on Form 10-Q for the second fiscal quarter ended March 31, 2007 filed with the Securities and Exchange Commission, as well as other filings that the comp
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
(Date:3/2/2015)... ANTONIO (PRWEB) March 02, 2015 After ... quality processes, customer service, pricing and long-term strategy, Blood ... its vendor of choice for member centers’ testing needs. ... centers and represents more than 30 percent of the ... member meeting. , “BCA is committed to drive cost ...
(Date:3/2/2015)... 2015 Over the last five years ... vendors seeking to expand their geographic presence and achieve ... to reach $6.2 billion by 2019 at CAGR of ... the U.S. and Canada and a major part of ... regions such as Asia-Pacific including China and India, Latin ...
(Date:3/2/2015)... PORTLAND, Oregon (PRWEB) March 02, 2015 ... world’s largest online healthcare certification programs, including ... compliance, and dietary supplement safety and classification, ... sellers of prescription eyeglasses. The new program, ... eyeglasses prescription verification, transparency regarding the identity ...
(Date:3/2/2015)... Prairie, WI (PRWEB) March 02, 2015 ... sciences consultancy focused on quality, regulatory and technical ... role as Chief Operating Officer. , Before ... of experience leading R&D teams in all aspects ... held leadership positions at Covidien (Medtronic), Regulatory Compliance ...
(Date:3/2/2015)... The Alliance for Bangladesh Worker Safety today ... to serve as chief safety officer. In this role, ... Bangladesh and guide remediation efforts in all factories from ... that the Alliance continues to bring world-class expertise to ... workers,” said Alliance Independent Chair Ellen Tauscher. “His role ...
Breaking Medicine News(10 mins):Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2
... NEW YORK, July 20 United Spinal Association,s ( www.UnitedSpinal.org ... premiere lifestyle-enhancing Expo designed to promote active living and independence for individuals with ... 3rd Annual Independence Expo will be held on Friday, August 7th and Saturday, ... , , At the opening ribbon ...
... , EDINA, Minn., July 20 Barbara ... women: , , "Never give up, because it,s never, ... years ago, at age 47, she was a stay-at-home mom who sold Mary Kay, ... unusual Mother,s Day present: her own staffing business. Barbara thought he was kidding. But ...
... ... services division. , ... Scottsdale, AZ (PRWEB) July 20, 2009 -- Angel Medflight, a worldwide life flight and ... J. Ward and Richard Siever to its client advocates legal services division. The ...
... Jesse ... to announce that participants of the AHRA conference set to take place in held in Las ... , ... AHRA Booth 553 - Jesse Salen, the VP of Sales and Technology at Online Radiology ...
... , , , ... and air ambulance service, is pleased to ... to its client advocates legal services division. The addition will ... , "All too often, health insurance companies today ...
... ... Dysport™ the newly FDA approved wrinkle remover and rival to Botox®. Founder ... the last six years and trained many other professionals on Botox® and ... the advanced uses of Botox for: hyperhidrosis (excessive sweating) and nervous tics ...
Cached Medicine News:Health News:United Spinal Association's 2009 Independence Expo Aug 7th-8th in Orlando: Improving Life for the Disabled and the Aging 2Health News:United Spinal Association's 2009 Independence Expo Aug 7th-8th in Orlando: Improving Life for the Disabled and the Aging 3Health News:Emerging Woman Business Owner of the Year Winner Offers 5 Tips to New Women Business Owners 2Health News:Air Ambulance and Life Flight Service Angel Medflight Adds Two to Client Advocates Division 2Health News:Air Ambulance and Life Flight Service Angel Medflight Adds Two to Client Advocates Division 2Health News:Waging War on Wrinkles: Infini Cosmetic Associates Now Offers Recent FDA Approved Dysport - The Botox Alternative 2
... Premier is our top-of-the-line device. ... attributes of the Qwik-Let® Elite, ... Lan-X feature. The Lan-X technology ... protection in the removal and ...
... has become one of the industry's ... is due to the great number ... design and function of the Qwik-Let ... priced for far less than most ...
... new Finnpipette Focus from Thermo Labsystems was ... performance. Advanced features such as the ... volume adjustment on microvolumes help to define ... channel pipettes. The new interchangeable handle plate ...
... new Finnpipette Focus from Thermo Labsystems was ... performance. Advanced features such as the ... volume adjustment on microvolumes help to define ... channel pipettes. The new interchangeable handle plate ...
Medicine Products: